Chimeric OspA proteins and methods of use thereof
View Patent ↗The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.
1. An isolated polypeptide selected from the group consisting of:
(a) an isolated polypeptide comprising an amino acid sequence having at least 91 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 8;
(b) an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 8; and
(c) an isolated polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 8.
2. A composition comprising the isolated polypeptide of claim 1 and a pharmaceutically acceptable carrier.
3. An immunogenic composition comprising the composition of claim 2 and an adjuvant.
4. A method for inducing an immunological response in a subject, the method comprising the step of administering the composition of claim 3 to the subject in an amount effective to induce an immunological response.
5. The isolated polypeptide of claim 1 comprising an amino acid sequence having at least 92 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 8.
6. The isolated polypeptide of claim 1 comprising an amino acid sequence having at least 93 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 8.
7. The isolated polypeptide of claim 1 comprising an amino acid sequence having at least 94 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 8.
8. The isolated polypeptide of claim 1 comprising an amino acid sequence having at least 95 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 8.
9. The isolated polypeptide of claim 1 comprising an amino acid sequence having at least 96 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 8.
10. The isolated polypeptide of claim 1 comprising an amino acid sequence having at least 97 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 8.
11. The isolated polypeptide of claim 1 comprising an amino acid sequence having at least 98 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 8.
12. The isolated polypeptide of claim 1 comprising an amino acid sequence having at least 99 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 8.
13. The isolated polypeptide of claim 1 consisting of the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 8.
14. A composition comprising the isolated polypeptide of claim 13 and a pharmaceutically acceptable carrier.
15. An immunogenic composition comprising the composition of claim 14 and an adjuvant.
16. A vaccine composition comprising an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2 or 8 and a pharmaceutically acceptable carrier, wherein the composition provides protection against infection by Borrelia burdorferi sensu stricto and Borrelia afzelii.
17. A method for preventing a Borrelia infection or Lyme disease in a subject caused by Borrelia burdorferi sensu stricto or Borrelia afzelii , the method comprising the step of administering the vaccine composition of claim 16 to the subject in an amount effective to prevent the Borrelia infection or Lyme disease.